In Vitro Assessments of Antimicrobial Activity

Awarded Vendors: Utah State University. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: University of Saskatchewan. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: University of Louisville. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: University of Louisville. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: University of Cincinnati. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: University of Alabama at Birmingham. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Southern Research Institute. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Southern Research Institute. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: New York University School of Medicine. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: List Biological Laboratories. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Jones Microbiology Institute. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Infectious Disease Research Institute. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Infectious Disease Research Institute. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: The Geneva Foundation. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: The Geneva Foundation. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Colorado State University. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: Colorado State University. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: American Type Culture Collection. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: American Type Culture Collection. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: American Type Culture Collection. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Awarded Vendors: American Type Culture Collection. Contract Award Dollar Amount: IDIQ Guaranteed Minimum: $2,500 ; Maximum Ordering Limit: $30M. Contract Award Date: 2019-01-11.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID) has a requirement to support in vitro testing to assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases.

Description

NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide a broad and flexible range of in vitro assessment capabilities to the extramural research community to evaluate promising candidate countermeasures against the more than 270 pathogens, toxins, and vectors (PTVs) that are within the purview of DMID. In vitro assay capabilities include: product screening, assay development, and development of improved systems for culturing difficult to grow pathogens in vitro. These capabilities will allow the NIAID to respond to changing priorities as scientific and public health needs shift, including rapid responses to public health emergencies.

In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data that may be used by NIAID partners at other agencies in DHHS. Such data will facilitate the advancement of promising candidate medical countermeasures against priority bioterror agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile.

As background, in 2011, 14 institutions were awarded base Indefinite Delivery, Indefinite Quantity (IDIQ) contracts under the In Vitro Assessments of Antimicrobial Activity program. For this recompetition, NIAID anticipates awarding multiple IDIQ contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas of this solicitation. Awards are anticipated on or about August 2018, and are expected to be comprised of a 7 year ordering period. Offerors will be considered for contracts only in the Task Area(s) included in their proposal. Sample Task Orders will be provided in the RFP for the purpose of evaluating Offeror responses and capabilities. A successful Contractor may compete for task orders only in the Task Area(s) in which they are selected for award. The Task Areas of this solicitation are as follows:

Task Area A - Bacteria, Fungi, and Toxins
Task Area B - Viruses
Task Area C - Parasites and Vectors
Task Area D - In Vitro Models that Mimic In vivo Exposures of Candidate Compounds
Task Area E - Development of New Techniques to Culture Difficult to Grow Pathogens

For the purposes of this solicitation the following definitions will apply:

• Assays - in vitro procedures for determining biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation. In addition in vitro procedures for determining the concentration, and/or purity of a substance.
• Products - broadly defined and include therapeutic substances targeting the host or the pathogen.
• Pathogens - bacteria, viruses, parasites, and fungi, particularly NIAID Category A, B and C list of Priority Pathogens (https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens )
• Toxins - microbial toxins as they relate to human disease including toxins that are produced by NIAID Category A, B and C list of Priority Pathogens.
• Vectors - arthropods (usually insects) or mollusks that carry pathogens from infected to uninfected hosts.
• Reagents - biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins and vectors.

The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise or facilities required to perform all activities set forth in the Statement of Work. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through consortia agreements, partnerships, subcontracts, and/or consultants. However, contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order.

Any responsible Offeror may submit a proposal which will be considered by the Agency. This Request for Proposals (RFP) will be available electronically on or about December 1, 2017 and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted.

For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable.

Proposals must be submitted via the electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov. Follow the "How to Submit an Electronic Proposal" instructions provided on the eCPS website at: https://ecps.nih.gov/home/howto. Please note that creating an account to submit may take up to three (3) business days. Please apply for a new account early to allow enough time for the registration process.

.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID) has a requirement to support in vitro testing to assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases.

Description

NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide a broad and flexible range of in vitro assessment capabilities to the extramural research community to evaluate promising candidate countermeasures against the more than 270 pathogens, toxins, and vectors (PTVs) that are within the purview of DMID. In vitro assay capabilities include: product screening, assay development, and development of improved systems for culturing difficult to grow pathogens in vitro. These capabilities will allow the NIAID to respond to changing priorities as scientific and public health needs shift, including rapid responses to public health emergencies.

In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data that may be used by NIAID partners at other agencies in DHHS. Such data will facilitate the advancement of promising candidate medical countermeasures against priority bioterror agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile.

As background, in 2011, 14 institutions were awarded base Indefinite Delivery, Indefinite Quantity (IDIQ) contracts under the In Vitro Assessments of Antimicrobial Activity program. For this recompetition, NIAID anticipates awarding multiple IDIQ contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas of this solicitation. Awards are anticipated on or about August 2018, and are expected to be comprised of a 7 year ordering period. Offerors will be considered for contracts only in the Task Area(s) included in their proposal. Sample Task Orders will be provided in the RFP for the purpose of evaluating Offeror responses and capabilities. A successful Contractor may compete for task orders only in the Task Area(s) in which they are selected for award. The Task Areas of this solicitation are as follows:

Task Area A - Bacteria, Fungi, and Toxins
Task Area B - Viruses
Task Area C - Parasites and Vectors
Task Area D - In Vitro Models that Mimic In vivo Exposures of Candidate Compounds
Task Area E - Development of New Techniques to Culture Difficult to Grow Pathogens

For the purposes of this solicitation the following definitions will apply:

• Assays - in vitro procedures for determining biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation. In addition in vitro procedures for determining the concentration, and/or purity of a substance.
• Products - broadly defined and include therapeutic substances targeting the host or the pathogen.
• Pathogens - bacteria, viruses, parasites, and fungi, particularly NIAID Category A, B and C list of Priority Pathogens (https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens )
• Toxins - microbial toxins as they relate to human disease including toxins that are produced by NIAID Category A, B and C list of Priority Pathogens.
• Vectors - arthropods (usually insects) or mollusks that carry pathogens from infected to uninfected hosts.
• Reagents - biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins and vectors.

The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise or facilities required to perform all activities set forth in the Statement of Work. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through consortia agreements, partnerships, subcontracts, and/or consultants. However, contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order.

Any responsible Offeror may submit a proposal which will be considered by the Agency. This Request for Proposals (RFP) will be available electronically on or about December 1, 2017 and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted.

For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable.

Proposals must be submitted via the electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov. Follow the "How to Submit an Electronic Proposal" instructions provided on the eCPS website at: https://ecps.nih.gov/home/howto. Please note that creating an account to submit may take up to three (3) business days. Please apply for a new account early to allow enough time for the registration process.